Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

54.73 +0.51 (+0.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart ↗
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not... 
Via Benzinga
News headline image
Where Biomarin Pharmaceutical Stands With Analysts ↗
Over the past 3 months, 6 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021 ↗
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A... 
Via Benzinga
News headline image
Why BioMarin Pharmaceutical Stock Jumped by 10.3% on Friday ↗
The rare-disease specialist might now have a true franchise-level drug following the approval of Voxzogo. 
Via The Motley Fool
News headline image
BioMarin Stock Jumps As FDA Approval Unlocks Its 'Next Growth Inflection' ↗
The BioMarin drug treats achondroplasia, a form of short-limbed dwarfism. 
Via Investor's Business Daily
News headline image
FDA Conditionally Approves Biomarin's Dwarfism Drug ↗
The FDA has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) for Injection for achondroplasia. The approval comes for achondroplasia... 
Via Benzinga
News headline image
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
News headline image
BioMarin's Q3 Net Income Hit By Lower Product Sales ↗
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 14% Y/Y decrease in Q3 revenue to $408.7 million, missing the consensus estimate of $435.32 million. The decline... 
Via Benzinga
News headline image
BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transcript ↗
BMRN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Biomarin Pharmaceutical: Q3 Earnings Insights ↗
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More ↗
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit... 
Via Benzinga
News headline image
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug ↗
Stifel 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
News headline image
Price To Earnings Ratio Insights For Biomarin Pharmaceutical ↗
In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 ↗
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
News headline image
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder ↗
​​​​​​BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene... 
Via Benzinga
News headline image
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval ↗
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The... 
Via Benzinga
News headline image
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months ↗
All it will take is an FDA approval and a partial repeat of history. 
Via The Motley Fool
News headline image
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance ↗
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,... 
Via Talk Markets
News headline image
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance ↗
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to... 
Via Benzinga
News headline image
BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript ↗
BMRN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Biomarin Pharmaceutical: Q2 Earnings Insights ↗
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the... 
Via Benzinga
News headline image
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
News headline image
BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy ↗
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy... 
Via Benzinga
News headline image
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22 ↗
The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.